TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-16

Archived explainer. For the current picture see today's SMMT page.

Why Is SUMMIT THERAPEUTICS (SMMT) Stock Down Today?

By the Top Tier Newswire AI Desk · November 16, 2026 at 11:39 AM ET · reviewed against 22 wire stories

SUMMIT THERAPEUTICS (SMMT) is down -14.98% in the latest session. Our newswire has captured 22 stories on SMMT across 13 sources in the last 36 hours, with AI sentiment reading bearish (avg 31/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Summit Therapeutics (SMMT) shares fell 14.98% to $12.03, driven by the FDA’s decision to decline approval for its lung cancer drug, ivonescimab. The regulator issued a Complete Response Letter, indicating the therapy needs to demonstrate it can help patients live longer.

What Happened

The FDA issued a Complete Response Letter for the Biologics License Application covering ivonescimab. The agency stated that the drug showed a progression-free survival benefit but lacked statistically significant improvement in overall survival. This regulatory setback prompted immediate reactions from analysts. Barclays lowered its price target on the stock to $18 from $20 while maintaining an Equal Weight rating. Evercore ISI Group also adjusted its stance, lowering its price target to $33 while maintaining an Outperform rating. The move marks a significant hurdle for the next-generation cancer therapy, which is backed by AstraZeneca.

What The Data Shows

The stock opened at $11.56, representing an 18.3% gap down from the prior close of $14.15. Trading volume reached 10.7 million shares, which is 1.9 times the three-month daily average. The session high was $13.28 at 9:35 AM ET, while the low was $11.45 at 7:00 AM ET. The company has a market capitalization of $11.3 billion and is currently unprofitable, with trailing twelve-month earnings per share of negative $1.07. Revenue for the same period was negative 100.0%. The stock is trading near its 52-week low, with a range of $12.07 to $29.23. Over the last eight sessions, the stock had already declined 12.5% from $16.17 to $14.15. On November 16, 2026, the stock printed three fresh 52-week highs and ten fresh 52-week lows.

What To Watch

Investors will monitor how the company responds to the FDA’s feedback and whether it plans to resubmit the application. The broader biotech sector is also watching for potential sentiment shifts following recent regulatory decisions.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

SMMT by the numbers

Last: $12.03Session: -14.98%7 sessions: -16.70%Coverage: 22 stories / 13 sourcesAI sentiment: 31/100 (bearish)Mkt cap: $11.3B52w: $12.07 to $29.23
SMMT · Nov 16 session (5-min) · -16.25% vs prior close · updated 8:58 PM ET
$11.37$12.84$14.31prev close $14.15$11.857:00 AM10:12 AM1:25 PM4:37 PM7:50 PM7:00 AM · $11.657:05 AM · $11.667:10 AM · $12.257:15 AM · $12.517:20 AM · $12.217:25 AM · $12.427:30 AM · $12.457:35 AM · $12.257:40 AM · $12.207:45 AM · $12.167:50 AM · $12.207:55 AM · $12.188:00 AM · $12.008:05 AM · $11.928:10 AM · $12.018:15 AM · $12.258:20 AM · $12.408:25 AM · $12.058:30 AM · $12.168:35 AM · $12.278:40 AM · $12.218:45 AM · $12.208:50 AM · $12.208:55 AM · $12.029:00 AM · $12.019:05 AM · $12.199:10 AM · $12.229:15 AM · $12.309:20 AM · $12.259:25 AM · $12.749:30 AM · $12.969:35 AM · $12.719:40 AM · $12.969:45 AM · $13.029:50 AM · $12.749:55 AM · $12.7910:00 AM · $12.6910:05 AM · $12.3810:10 AM · $12.1210:15 AM · $12.2110:20 AM · $12.2810:25 AM · $12.2710:30 AM · $12.3310:35 AM · $12.4210:40 AM · $12.4610:45 AM · $12.4310:50 AM · $12.3610:55 AM · $12.2211:00 AM · $12.0711:05 AM · $12.1111:10 AM · $11.9211:15 AM · $12.1011:20 AM · $12.0911:25 AM · $12.1011:30 AM · $12.0611:35 AM · $12.0211:40 AM · $12.0311:45 AM · $12.0311:50 AM · $12.0611:55 AM · $12.1112:00 PM · $11.9712:05 PM · $11.9712:10 PM · $11.9412:15 PM · $11.9612:20 PM · $11.9612:25 PM · $12.0112:30 PM · $11.9812:35 PM · $11.9412:40 PM · $12.1212:45 PM · $12.0412:50 PM · $12.0512:55 PM · $12.131:00 PM · $12.071:05 PM · $12.031:10 PM · $11.961:15 PM · $11.971:20 PM · $11.961:25 PM · $11.981:30 PM · $11.821:35 PM · $11.881:40 PM · $11.821:45 PM · $11.801:50 PM · $11.721:55 PM · $11.782:00 PM · $11.882:05 PM · $11.912:10 PM · $11.812:15 PM · $11.822:20 PM · $11.802:25 PM · $11.902:30 PM · $11.892:35 PM · $11.862:40 PM · $11.802:45 PM · $11.772:50 PM · $11.762:55 PM · $11.753:00 PM · $11.663:05 PM · $11.663:10 PM · $11.653:15 PM · $11.713:20 PM · $11.533:25 PM · $11.643:30 PM · $11.673:35 PM · $11.683:40 PM · $11.683:45 PM · $11.683:50 PM · $11.763:55 PM · $11.824:00 PM · $11.824:05 PM · $11.754:15 PM · $11.834:20 PM · $11.824:25 PM · $11.874:30 PM · $11.844:40 PM · $12.004:45 PM · $12.005:05 PM · $11.935:15 PM · $11.835:30 PM · $11.935:35 PM · $11.855:55 PM · $11.906:05 PM · $11.836:15 PM · $11.836:25 PM · $11.856:30 PM · $11.987:05 PM · $11.857:10 PM · $11.857:15 PM · $11.857:20 PM · $11.837:25 PM · $11.837:30 PM · $11.857:45 PM · $11.877:50 PM · $11.85
AI sentiment, last 36h · averaged over 22 stories · 31/100 bearish
AI sentiment 31/100 (bearish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishTipRanks · sentiment 34 · Summit Therapeutics Receives FDA Complete Response Letter for IvonescimabTipRanks · 34Summit Therapeutics Receives FDA Complete Response Letter for IvonescimabStockTitan · sentiment 52 · San Mateo Midstream Announces Offering of $750 Million of Senior Notes Due 2031StockTitan · 52San Mateo Midstream Announces Offering of $750 Million of Senior Notes Due 2031The Fly · sentiment 48 · San Mateo Midstream announces offering of $750M senior notesThe Fly · 48San Mateo Midstream announces offering of $750M senior notesMarketWatch · sentiment 22 · The FDA declined to approve one of biotech’s most closely watched cancer drugsMarketWatch · 22The FDA declined to approve one of biotech’s most closely watched cancer drugsBarron's · sentiment 34 · Summit’s FDA Setback Is a Reality Check for Next-Gen Cancer DrugsBarron's · 34Summit’s FDA Setback Is a Reality Check for Next-Gen Cancer DrugsQuartz · sentiment 22 · FDA declined to approve Summit Therapeutics' lung cancer drugQuartz · 22FDA declined to approve Summit Therapeutics' lung cancer drugGuruFocus · sentiment 42 · SMMT Maintained by Evercore ISI Group -- Price Target Lowered to $33GuruFocus · 42SMMT Maintained by Evercore ISI Group -- Price Target Lowered to $33Stocktwits News · sentiment 34 · SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response LetterStocktwits News · 34SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Comple…
4d agoStocktwits NewsBEARISH 34Analyst

SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter

Barclays lowered its price target on Summit Therapeutics to $18 from $20 while maintaining an 'Equal Weight' rating, according to The Fly.

4d agoGuruFocusBEARISH 42Analyst

SMMT Maintained by Evercore ISI Group -- Price Target Lowered to $33

Summit Therapeutics Inc (SMMT) Analyst Rating Update On October 3, 2023, Summit Therapeutics Inc (SMMT) received an updated rating action from Evercore ISI G

4d agoQuartzBEARISH 22General

FDA declined to approve Summit Therapeutics' lung cancer drug

4d agoBarron'sBEARISH 34General

Summit’s FDA Setback Is a Reality Check for Next-Gen Cancer Drugs

Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.

4d agoMarketWatchBEARISH 22General

The FDA declined to approve one of biotech’s most closely watched cancer drugs

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

4d agoThe FlyNEUTRAL 48General

San Mateo Midstream announces offering of $750M senior notes

4d agoStockTitanNEUTRAL 52General

San Mateo Midstream Announces Offering of $750 Million of Senior Notes Due 2031

4d agoTipRanksBEARISH 34Product/PR

Summit Therapeutics Receives FDA Complete Response Letter for Ivonescimab

Summit Therapeutics ( ($SMMT) ) has provided an announcement. On November 15, 2026, Summit Therapeutics announced that the FDA issued a CRL for its BLA covering ivo...

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on SMMT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier SMMT move explainers: 2026-11-18 · 2026-11-17 · 2026-11-16 · 2026-09-30 · 2026-09-29 · 2026-09-14 · 2026-09-04 · 2026-09-03 · 2026-09-01 · 2026-08-27 · 2026-08-26 · 2026-08-25 · 2026-08-17